![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication September 3, 2004.
Revised October 28, 2004.
Accepted for publication October 28, 2004.
Oxidant stress - induced activation of poly(ADP-ribose) polymerase (PARP) plays a role in the pathogenesis of various cardiovascular diseases. We have now investigated the role of PARP in the process of cardiac remodeling and heart failure in a mouse model of heart failure induced by transverse aortic constriction (banding). The catalytic activity of PARP was inhibited by the potent PARP inhibitor INO-1001 or by PARP-1 genetic deficiency. PARP inhibition prevented the pressure-overload induced decrease in cardiac contractile function, despite the pressure gradient between both carotid arteries being comparable in the two experimental groups. The development of hypertrophy, the formation of collagen in the hearts, and the mitochondrial-to nuclear translocation of the cell death factor AIF (apoptosis-inducing factor) were attenuated by PARP inhibition. The ability of the inhibitor to block the catalytic activity of PARP was confirmed by immuno-histochemical detection of poly(ADP-ribose), the product of the enzyme in the heart. Plasma levels of INO-1001, as measured at the end of the experiments, were in the concentration range sufficient to block the oxidant-mediated activation of PARP in murine cardiac myocytes in vitro. Myocardial hypertrophy and AIF translocation was also reduced in PARP-1 deficient mice undergoing aortic banding, when compared to their wild-type counterparts. Overall, the current results demonstrate the importance of poly(ADP-ribos)ylation in the pathogenesis of banding-induced heart failure.
Key words:
Apoptosis, DNA, heart, necrosis, nitric oxide, oxidative stress
This article has been cited by other articles:
|
|
 |
|
  C. Szabo, A. Biser, R. Benko, E. Bottinger, and K. Susztak Poly(ADP-Ribose) Polymerase Inhibitors Ameliorate Nephropathy of Type 2 Diabetic Leprdb/db Mice Diabetes, November 1, 2006; 55(11): 3004 - 3012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Pillai, M. Gupta, S. B. Rajamohan, R. Lang, J. Raman, and M. P. Gupta Poly(ADP-ribose) polymerase-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1545 - H1553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. O. Hassa, S. S. Haenni, M. Elser, and M. O. Hottiger Nuclear ADP-Ribosylation Reactions in Mammalian Cells: Where Are We Today and Where Are We Going? Microbiol. Mol. Biol. Rev., September 1, 2006; 70(3): 789 - 829. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Pillai, A. Isbatan, S.-i. Imai, and M. P. Gupta Poly(ADP-ribose) Polymerase-1-dependent Cardiac Myocyte Cell Death during Heart Failure Is Mediated by NAD+ Depletion and Reduced Sir2{alpha} Deacetylase Activity J. Biol. Chem., December 30, 2005; 280(52): 43121 - 43130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tapodi, B. Debreceni, K. Hanto, Z. Bognar, I. Wittmann, F. Gallyas Jr., G. Varbiro, and B. Sumegi Pivotal Role of Akt Activation in Mitochondrial Protection and Cell Survival by Poly(ADP-ribose)polymerase-1 Inhibition in Oxidative Stress J. Biol. Chem., October 21, 2005; 280(42): 35767 - 35775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Cheng, S. P. Johnson, S. T. Keir, J. A. Quinn, F. Ali-Osman, C. Szabo, H. Li, A. L. Salzman, M. E. Dolan, P. Modrich, et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft Mol. Cancer Ther., September 1, 2005; 4(9): 1364 - 1368. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
